NCT03957096

A Safety Study of SGN-CD47M in Patients With Solid Tumors

Terminated Phase 1 Last updated 17 September 2020

What this trial tests

Phase 1 trial testing SGN-CD47M in Soft Tissue Sarcoma in 16 participants. Terminated before completion.

Timeline

17 July 2019

Primary endpoint
14 September 2020

14 September 2020

Quick facts

Lead sponsor	Seagen Inc.
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	16
Start date	17 July 2019
Primary completion	14 September 2020
Estimated completion	14 September 2020
Sites	5 locations across United States

Drugs / interventions tested

• SGN-CD47M — full drug profile →

Conditions studied

• Soft Tissue Sarcoma — all drugs for Soft Tissue Sarcoma →
• Colorectal Cancer — all drugs for Colorectal Cancer →
• Head and Neck Squamous Cell Carcinoma — all drugs for Head and Neck Squamous Cell Carcinoma →
• Non-small Cell Lung Carcinoma — all drugs for Non-small Cell Lung Carcinoma →

Sponsor

Seagen Inc. — full company profile →

Who can join

18 and older, any sex, with Soft Tissue Sarcoma or Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial will study SGN-CD47M to find out whether it is an effective treatment for different types of solid tumors and what side effects (unwanted effects) may occur. The study will have two parts. Part A of the study will find out how much SGN-CD47M should be given for treatment and how often. Part B of the study will use the dose found in Part A and look at how safe and effective the treatment is.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Emerging phagocytosis checkpoints in cancer immunotherapy.
   Liu Y, Liu Y, Wang Y, Yang Y, et al · · 2023 · cited 186× · PMID 36882399 · DOI 10.1038/s41392-023-01365-z
2. Targeting macrophages in hematological malignancies: recent advances and future directions.
   Li W, Wang F, Guo R, Bian Z, et al · · 2022 · cited 126× · PMID 35978372 · DOI 10.1186/s13045-022-01328-x
3. Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy.
   Giannone G, Ghisoni E, Genta S, Scotto G, et al · · 2020 · cited 119× · PMID 32575899 · DOI 10.3390/ijms21124414
4. Barriers and opportunities in pancreatic cancer immunotherapy.
   Ju Y, Xu D, Liao MM, Sun Y, et al · · 2024 · cited 83× · PMID 39266715 · DOI 10.1038/s41698-024-00681-z
5. CD47-SIRPα blocking-based immunotherapy: Current and prospective therapeutic strategies.
   Bouwstra R, van Meerten T, Bremer E. · · 2022 · cited 82× · PMID 35908284 · DOI 10.1002/ctm2.943
6. Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed.
   Qu T, Li B, Wang Y. · · 2022 · cited 66× · PMID 35418166 · DOI 10.1186/s40364-022-00373-5
7. Dysregulated tumor-associated macrophages in carcinogenesis, progression and targeted therapy of gynecological and breast cancers.
   Xu T, Yu S, Zhang J, Wu S. · · 2021 · cited 66× · PMID 34717710 · DOI 10.1186/s13045-021-01198-9
8. Preclinical and Clinical Development of Therapeutic Antibodies Targeting Functions of CD47 in the Tumor Microenvironment.
   Kaur S, Cicalese KV, Bannerjee R, Roberts DD. · · 2020 · cited 53× · PMID 33244513 · DOI 10.1093/abt/tbaa017